Changchun University of Chinese Medicine, 1035 Bo Shuo Road, Changchun City, Jilin Province, China.
Department of Hepatology, First Affiliated Hospital to Changchun University of Chinese Medicine, 1478 Gongnong Road, Changchun City, Jilin Province, China.
Medicine (Baltimore). 2021 Oct 8;100(40):e27497. doi: 10.1097/MD.0000000000027497.
Primary liver cancer (PLC) is a common cancer, and its morbidity and mortality are ranked 6th and 3rd in the world for malignant tumors, respectively. And this number is still on the rise, seriously endangering people's health. In recent years, acupuncture combined with Chinese herbal medicine have been widely used in the treatment of PLC, and there are few restrictions. However, we have not found a meta-analysis of their synergistic effects. Therefore, this systematic review and meta-analysis will evaluate the efficacy and acupuncture combined with Chinese herbal medicine in the treatment of primary liver cancer.
We will search the following databases from inception up to August 20, 2021: PubMed, Web of Science, Embase, AMED, Cochrane Library, CNKI, VIP, CBM, and Wanfang. There will be no restrictions regarding publication date or language. We will apply a combination of medical keywords and words, including "acupuncture," "Chinese herbal medicine" and "primary liver cancer". Additionally, we will manually search all reference lists from relevant systematic reviews to find other eligible studies. We will use the random effects model in REVMAN v5.3 for meta-analysis. The study for acupuncture combined with Chinese herbal medicine in the treatment of PLC was a randomized controlled study. Two researchers will independently review the research selection, data extraction, and research quality assessments. Finally, we will observe the outcome measures.
This study will provide evidence-based medical evidence for the treatment of PLC with a combination of acupuncture and Chinese herbal medicine, and provide new ideas and methods for the treatment of PLC.Registration number: INPLASY202180103.
原发性肝癌（PLC）是一种常见的癌症，其发病率和死亡率在恶性肿瘤中分别位居世界第 6 位和第 3 位。而且这个数字还在不断上升，严重威胁着人们的健康。近年来，针灸结合中药在 PLC 的治疗中得到了广泛的应用，而且限制较少。然而，我们尚未发现其协同作用的荟萃分析。因此，本系统评价和荟萃分析将评估针灸结合中药治疗原发性肝癌的疗效。
我们将从成立到 2021 年 8 月 20 日，检索以下数据库：PubMed、Web of Science、Embase、AMED、Cochrane Library、CNKI、VIP、CBM 和万方。不限制出版日期或语言。我们将采用医学关键词和词汇的组合，包括“针灸”、“中草药”和“原发性肝癌”。此外，我们将手动搜索所有相关系统评价的参考文献列表，以找到其他合格的研究。我们将使用 REVMAN v5.3 中的随机效应模型进行荟萃分析。针灸结合中药治疗 PLC 的研究是一项随机对照研究。两名研究人员将独立审查研究选择、数据提取和研究质量评估。最后，我们将观察结局指标。
本研究将为针灸结合中药治疗 PLC 提供循证医学证据，并为 PLC 的治疗提供新的思路和方法。注册号：INPLASY202180103。
